Evaluation of different strategies to improve the management of Helicobacter Pylori infection at the primary care level: training sessions increase prescription appropriateness of treatment regimens

Alfaro, Enrique (Universidad de Zaragoza) ; Martínez-Domínguez, Samuel J. (Universidad de Zaragoza) ; Laredo, Viviana (Universidad de Zaragoza) ; Lanas, Ángel (Universidad de Zaragoza) ; Sostres, Carlos (Universidad de Zaragoza)

Resumen: Helicobacter pylori infection (H. pylori) is mainly managed at the primary care level. Our group previously performed a study demonstrating that providing specific counselling (SC) to primary care practitioners (PCPs) who requested a urea breath test (UBT) improved treatment management but not indications for H. pylori tests. SC was given in the form of a personal letter addressed to PCPs with UBT results which contained information about accepted UBT indications and a Helicobacter pylori treatment algorithm. The purpose of the present study was to evaluate the effect of training sessions (TS) on UBT indications, antibiotic prescriptions and eradication rates. This was a quasi-experimental study performed at primary care centres (PCCs). Phase I included 399 patients diagnosed with H. pylori infection after providing SC to PCPs. Phase II included 400 H. pylori-positive patients after giving TS to PCPs who had already received SC (100 from PCCs with TS and 300 from PCCs without TS). An improved trend in the appropriate indication of H. pylori diagnosis was observed between Phase I and PCCs with TS in Phase II (57.5% vs. 67%; p = 0.06). TS improved appropriate prescriptions in PCCs with TS compared to PCCs that only received SC in Phase I and II (94% vs. 75.3%, p = 0.01; 94% vs. 85.6%, p = 0.04, respectively). Eradication rates showed no differences between groups. In conclusion, training sessions after specific counselling improved antibiotic prescription appropriateness but not eradication rates.

Idioma: Inglés

DOI: 10.3390/antibiotics11121746

Año: 2022

Publicado en: Antibiotics 11, 12 (2022), 1746 [10 pp.]
ISSN: 2079-6382

Factor impacto JCR: 4.8 (2022)

Categ. JCR: PHARMACOLOGY & PHARMACY rank: 65 / 278 = 0.234 (2022) - Q1 - T1
Categ. JCR: INFECTIOUS DISEASES rank: 35 / 96 = 0.365 (2022) - Q2 - T2

Factor impacto CITESCORE: 5.5 - Biochemistry, Genetics and Molecular Biology (Q2) - Immunology and Microbiology (Q2) - Pharmacology, Toxicology and Pharmaceutics (Q2) - Medicine (Q2)

Factor impacto SCIMAGO: 0.792 - Pharmacology, Toxicology and Pharmaceutics (miscellaneous) (Q1) - Infectious Diseases (Q2) - Microbiology (medical) (Q2) - Pharmacology (medical) (Q2) - Biochemistry (Q2) - Microbiology (Q2)

Tipo y forma: Artículo (Versión definitiva)

Área (Departamento): Area Medicina (Dpto. Medicina, Psiqu. y Derm.)